A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis - Reply

被引：2

作者：

Bonneterre, ME ^{[1
]}

Bonneterre, J ^{[1
]}

机构：

[1] Ctr Oscar Lambret, F-59000 Lille, France

来源：

ANNALS OF ONCOLOGY | 2006年 / 17卷 / 05期

关键词：

D O I：

10.1093/annonc/mdj074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 3 条

[1] Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial [J].

Extra, J. M. ;

Cognetti, F. ;

Maraninch, D. ;

Snyder, R. ;

Mauriac, L. ;

Tubiana-Hulin, M. ;

Chan, S. ;

Grimes, D. ;

Anton, A. ;

Marty, M. .

EJC SUPPLEMENTS, 2004, 2 (03) :125-126

[2] A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis [J].

Norum, J ;

Risberg, T ;

Olsen, JA .

ANNALS OF ONCOLOGY, 2005, 16 (06) :909-914

[3] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

← 1 →